Ovid Therapeutics Reports Q1 2025 Net Loss of $10.2M, EPS Improves to $0.14 as Revenues Slip to $130K

Reuters
13 May
Ovid <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Q1 2025 Net Loss of $10.2M, EPS Improves to $0.14 as Revenues Slip to $130K

Ovid Therapeutics Inc., a biopharmaceutical company focused on developing treatments for brain conditions, announced its financial results for the first quarter of 2025. As of March 31, 2025, the company reported $43.0 million in cash, cash equivalents, and marketable securities. Revenues from royalty agreements were $130,000, reflecting a decrease from $148,000 in the same period the previous year. The company reported a net loss of $10.2 million for the first quarter, compared to a net loss of $11.7 million during the same period in 2024. Research and development expenses were reduced to $6.7 million from $10.4 million in the prior year's first quarter, attributed to organizational restructuring. General and administrative expenses also decreased to $6.0 million from $7.2 million in 2024, driven by cost-reduction efforts. Total operating expenses were reported at $12.7 million, down from $17.6 million in the previous year. In terms of business updates, Ovid's lead program, OV329, is on track to provide key safety and biomarker data later in 2025, and the company has initiated a Phase 1 study of OV350, with safety and tolerability results expected by year-end. The company anticipates its cash reserves will support operations and development programs into the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450097-en) on May 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10